AstraZeneca Merck Obtain Orphan Drug Designation for Lynparza for Pancreatic Cancer

AstraZeneca, Merck Obtain Orphan Drug Designation for Lynparza for Pancreatic Cancer

16:14 EDT 16 Oct 2018 | Pharmaceutical Processing

News
Lynparza is currently being investigated as maintenance therapy in patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Contributed Author: 
AstraZeneca and Merck
Topics: 

More From BioPortfolio on "AstraZeneca, Merck Obtain Orphan Drug Designation for Lynparza for Pancreatic Cancer"